Regeneus Limited (ASX: RGS), a healthcare company which deals with regenerative medicine announced the appointment of Mr. Leo Lee as their new Chief Executive officer and member of the board with immediate effect. He will be replacing the outgoing CEO John Martin who served the organization for ten years.
The Board welcomes its new CEO Mr. Leo Lee to the company. The board along with the appointment of its new CEO tried to maintain its continuous focus towards becoming a global regenerative medicine company who develops therapeutics for osteoarthritis, dermatology, and neuropathic pain and also maximize its shareholder’s value. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
On the other hand, the Board of members thanked Mr. John Martin for his valuable ten years contribution towards the company. The Board highly appreciated his vision and efforts in developing Progenza and Sygenus. Mr. John Martin will now serve the board as the non-executive director.
Mr. Leo Lee also feels excited to join as the CEO of the company, and he states that there are tremendous opportunities for accelerating patients’ access throughout the world while creating shareholders value.
In December 2017, Mr. Leo Lee joined the board as an independent non-executive director. Being a part of the board, he had gained valuable insights into the company business and strategy, and since then he has also developed a relationship with other board members and the senior management team of the company.
At present, Leo is stepping towards securing the first primary clinical license of Progenza in Japan. The company is under the partnership discussion with potential licensees for a very long time. However, the company is confident about the successful commercial outcome. The company has much higher expectations from Leo that he will be successful in maximizing the company’s asset value.
Leo also has massive networks in the pharmaceutical industry, and he has a good command over the Chinese and Japanese language which will be beneficial for the company for developing and managing its business in Japan and another Asia Pacific region.
In Japan, Leo was the former president at Merck and Allergan. At Merck & Co, IQVIA and Accelrys, he was also responsible for the commercial and sales roles. Leo has completed his bachelor’s degree from the University of California Los Angeles in Bachelor of Science in Molecular Genetics and Microbiology.
The official listing date of RGS on ASX is 19 September 2013, where the performance of the company remained negative till last five years. In last one year, RGS’s performance was 37.50%.
Based on the skills and expertise of Mr. Leo Lee, it appears that the investors and the shareholders have faith in him that he would be successful in taking the company to the next level of success. With an announcement of Mr. Leo Lee as the new CEO, the share price of RGS increased by 6.061%, by the end of the trading on 23 January 2019, the opening price of the share on 24 January 2019 is A$0.175 with the stock holding a market capitalization of A$36.55 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.